AstraZeneca's Alexion to Buy Gene Therapies Portfolio for Up to $1 Billion From Pfizer
28 Juli 2023 - 9:10AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca said Friday that its Alexion division will buy a
portfolio of preclinical rare-disease gene therapies from Pfizer
for up to $1 billion, plus tiered royalties on sales.
The London-listed pharmaceutical giant said the definitive
purchase and license agreement will bring Alexion--its rare-disease
business--several new resources, which will build on the company's
combined capabilities in genomic medicine. The company said it
intends to develop new genetic therapies with improved safety and
efficacy profiles.
AstraZeneca said it plans to close the transaction in the third
quarter, subject to closing conditions being met.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
July 28, 2023 02:55 ET (06:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
